[{"data":1,"prerenderedAt":-1},["ShallowReactive",2],{"health-studies-list:{\"overallStatus\":[\"RECRUITING\",\"AVAILABLE\",\"NOT_YET_RECRUITING\"],\"leadSponsorName\":\"Fang Wang\",\"orderBy\":\"LastUpdateSubmitDate:desc\",\"size\":25,\"offset\":0}":3,"health-study-condition:":66},{"pageToken":4,"total":5,"offset":6,"count":5,"results":7},null,2,0,[8,41],{"id":9,"slug":10,"hasResults":11,"nctId":12,"briefTitle":13,"officialTitle":14,"acronym":4,"eligibilityCriteria":15,"healthyVolunteers":11,"sex":16,"minAge":17,"maxAge":18,"enrollmentInfo":19,"targetDuration":4,"studyType":22,"phases":23,"briefSummary":25,"conditions":26,"keywords":4,"overallStatus":28,"whyStopped":4,"lastUpdateSubmitDate":29,"lastUpdatePostDateStruct":30,"startDateStruct":33,"completionDateStruct":35,"leadSponsor":37,"locationsCount":40},"100630536","doxycycline-and-progestin-therapy-for-chronic-endometritisce-in-patients-with-recurrent-reproductive-failurerrf-100630536",false,"NCT07488949","Doxycycline and Progestin Therapy for Chronic Endometritis(CE) in Patients With Recurrent Reproductive Failure(RRF)","Clinical Efficacy and Pregnancy Outcomes of Doxycycline Combined With Medroxyprogesterone Acetate Therapy for Chronic Endometritis(CE) in Patients With Recurrent Reproductive Failure(RRF): A Prospective Randomized Controlled Trial","Inclusion Criteria:\n\n* women aged 20-45 years;\n* plans to conceive within 12 months;\n* chronic endometritis(CE) confirmed by endometrial CD138 immunohistochemistry (IHC);\n* a diagnosis of recurrent reproductive failure(RRF);\n* willingness to undergo hysteroscopy and endometrial biopsy;\n* no contraindications to the study medications.\n\nExclusion Criteria:\n\n* acute genital tract infection, gynecologic malignancy, endometrial hyperplasia, or uterine fibroids;\n* pregnancy or lactation;\n* contraindications to hysteroscopy or anesthesia;\n* use of antibiotics, glucocorticoids, estrogens, or progestins within 3 months before trial initiation;\n* allergy to doxycycline or medroxyprogesterone acetate(MPA);\n* abnormal semen parameters in the male partner.","FEMALE","20 Years","45 Years",{"count":20,"type":21},1000,"ESTIMATED","INTERVENTIONAL",[24],"NA","A Prospective Randomized Controlled Trial, the goal of this clinical trial is to evaluate the efficacy and safety of doxycycline alone versus doxycycline plus medroxyprogesterone acetate (MPA) in women with chronic endometritis (CE), and to assess subsequent reproductive outcomes. Participants will be randomly assigned to one of two groups and will receive the assigned treatment. Participants will be followed for reproductive outcomes, including pregnancy , ongoing pregnancy, spontaneous miscarriage, and live birth.",[27],"Chronic Endometritis","RECRUITING","2026-03-18",{"date":31,"type":32},"2026-03-23","ACTUAL",{"date":34,"type":32},"2024-04-09",{"date":36,"type":21},"2031-12-31",{"name":38,"class":39},"Fang Wang","OTHER",1,{"id":42,"slug":43,"hasResults":11,"nctId":44,"briefTitle":45,"officialTitle":46,"acronym":4,"eligibilityCriteria":47,"healthyVolunteers":11,"sex":16,"minAge":48,"maxAge":18,"enrollmentInfo":49,"targetDuration":4,"studyType":22,"phases":51,"briefSummary":52,"conditions":53,"keywords":55,"overallStatus":57,"whyStopped":4,"lastUpdateSubmitDate":58,"lastUpdatePostDateStruct":59,"startDateStruct":61,"completionDateStruct":63,"leadSponsor":65,"locationsCount":40},"100622539","topefilgrastim-injection-in-the-treatment-of-high-risk-pregnant-patients-with-preeclampsia-100622539","NCT07384936","Topefilgrastim Injection in the Treatment of High-Risk Pregnant Patients With Preeclampsia","A Prospective, Controlled Study to Assess the Preliminary Efficacy and Safety of Topefilgrastim Injection in High-Risk Pregnant Patients With Preeclampsia.","Inclusion Criteria:\n\n* Voluntarily participate in the study, be able to understand, and sign the informed consent form.\n* Aged 18 to 45 years (inclusive) at the time of signing the informed consent form.\n* Assessed as high-risk for preeclampsia at gestational weeks 11-13, defined as either:\n\nA risk value of ≥1\u002F100 based on the simplified Fetal Medicine Foundation (FMF) model, OR A high-risk result from serum biomarker screening (sFlt-1, PLGF, sFlt-1\u002FPLGF ratio). (See Appendix for details)\n\n* Gestational weeks 11-13 at enrollment.\n* Singleton intrauterine pregnancy (confirmed by transvaginal or transabdominal ultrasound).\n\nExclusion Criteria:\n\n* History of psychiatric disorder not adequately controlled by medication.\n* Unexplained vaginal bleeding at screening.\n* Known uterine malformation.\n* Evidence of positive serology for HIV, HBV (HBsAg positive), HCV (anti-HCV antibody positive), or syphilis.\n* Known proliferative retinopathy.\n* Presence of severe organic disease or any other condition that, in the judgment of the investigator, makes the subject unsuitable for study participation.\n* Planned or current use of medications with potential drug-drug interactions with human granulocyte colony-stimulating factor (G-CSF) analogs, such as lithium.\n* Known allergy to rhG-CSF products or their components, or allergy to recombinant human proteins\u002Fpeptides derived from E. coli.","18 Years",{"count":50,"type":21},100,[24],"This study is an open-label, prospective investigation designed to enroll 100 high-risk pregnant subjects with preeclampsia (PE). Participants will be allocated in a 2:2:1 ratio to one of three groups: the Topefilgrastim 0.5mg\u002Fbiweekly group, the Topefilgrastim 1mg\u002Fbiweekly group, or the control group, based on investigator judgment and patient preference. The overall study consists of three parts: a screening period, a treatment period, and a follow-up period.",[54],"Preeclampsia",[54,56],"Topefilgrastim Injection","NOT_YET_RECRUITING","2026-01-26",{"date":60,"type":32},"2026-02-03",{"date":62,"type":21},"2026-01-31",{"date":64,"type":21},"2027-12",{"name":38,"class":39},""]